Lupin Ltd. has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Valbenazine Capsules, 40 mg and 80 mg, to market a generic equivalent of Ingrezza Capsules, 40 mg and 80 mg, of Neurocrine Biosciences, Inc.

Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity. The product will be manufactured at Lupin’s Nagpur facility in India. Valbenazine Capsules, 40 mg and 80 mg (RLD Ingrezza) had estimated annual sales of USD 1621 million in the US.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the US by prescriptions. The company invested 7.9 percent of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, and more than 20,000 professionals working globally, and has been consistently recognized as a ‘great place to work’ in the Biotechnology & Pharmaceuticals sector.